MedTech Dive February 25, 2025
The acquisition will add dialysis-related water testing to Quest’s portfolio and position the company to perform the tests and other end-stage kidney disease services for Fresenius Medical Care.
Dive Brief:
- Quest Diagnostics has struck a deal to buy kidney disease laboratory testing service assets from Fresenius Medical Care, the companies said Monday.
- The acquisition will add dialysis-related water testing to Quest’s portfolio. Quest will perform the tests and other end-stage kidney disease laboratory services for Fresenius Medical Care’s dialysis centers in the U.S.
- Quest, which has not disclosed the value of takeover, completed eight buyouts last year, but CEO Jim Davis recently told investors the company would “moderate” its dealmaking pace in 2025.
Dive Insight:
The takeover covers...
Today's Sponsors
Today's Sponsor